Grown Rogue International (GRUSF) Income from Non-Controlling Interests (2013 - 2026)
Grown Rogue International (GRUSF) posted quarterly Income from Non-Controlling Interests of -$488826.0 for Q1 2026, down 239.26% year-over-year from $351029.0 in Q1 2025, and up 100.0% quarter-over-quarter from -$321.7 billion in Q4 2025.
Grown Rogue International (GRUSF) Income from Non-Controlling Interests (2013 - 2026) Analysis & Trends
Grown Rogue International's Income from Non-Controlling Interests history runs 11 years deep, the most recent figure standing at -$488826.0 for Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests fell 239.26% year-over-year to -$488826.0; the TTM figure through Mar 2026 stood at -$182.1 billion (down 29.91% YoY), while the FY2025 annual figure was -$1.5 million, down 8499.04% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at -$488826.0, up from -$321.7 billion in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $139.6 billion in Q3 2025, with the low at -$321.7 billion in Q4 2025.
- The 5-year median for Income from Non-Controlling Interests is $30728.0 (2024), against an average of -$21.5 billion.
- The sharpest annual moves came in 2022 and 2024: Income from Non-Controlling Interests surged 11432.01% in 2022, then tumbled 915246434.11% in 2024.
- Grown Rogue International's Income from Non-Controlling Interests stood at $564607.0 in 2022, then plunged by 94.76% to $29607.0 in 2023, then sank by 915246434.11% to -$271.0 billion in 2024, then fell by 18.72% to -$321.7 billion in 2025, then soared by 100.0% to -$488826.0 in 2026.
- Business Quant data shows GRUSF's Income from Non-Controlling Interests at -$488826.0 in Q1 2026, -$321.7 billion in Q4 2025, and $139.6 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.45 Bn | 29.77 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Grown Rogue International | 109.32 Mn | 97.78 Mn | 5.37 Mn | -211,812.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -211,812.00 |
| Mar 31, 2026 | -488,826.00 |
| Dec 31, 2025 | -321.70 Bn |
| Sep 30, 2025 | 139.57 Bn |
| Jun 30, 2025 | 99,131.00 |
| Mar 31, 2025 | -144,088.00 |
| Dec 31, 2024 | -270.98 Bn |
| Sep 30, 2024 | 130.78 Bn |
| Jun 30, 2024 | 80,039.42 |
| Mar 31, 2024 | 30,728.00 |
| Dec 31, 2023 | 29,607.00 |
| Oct 31, 2023 | 210,129.00 |
| Jul 31, 2023 | 119,093.00 |
| Apr 30, 2023 | -867.00 |
| Jan 31, 2023 | -339,408.00 |
| Jan 31, 2022 | 564,607.00 |
| Oct 31, 2021 | 1.12 Mn |
| Jul 31, 2021 | 283,126.00 |
| Apr 30, 2021 | -15,306.00 |
| Jan 31, 2021 | 4,896.00 |